You are here

  • Home
  • Archive
  • Volume 30, Issue Suppl 3
  • 36 Prognostic value and association with veliparib benefit of modeled CA-125 elimination kinetics (KELIM) in patients with newly diagnosed ovarian cancer: analysis from the VELIA/GOG-3005 study

Alerts

Article menu

Download PDFPDF

Oral Poster – TAPED
Oral Featured Posters – Pre-Recorded
IGCS20_1102
36 Prognostic value and association with veliparib benefit of modeled CA-125 elimination kinetics (KELIM) in patients with newly diagnosed ovarian cancer: analysis from the VELIA/GOG-3005 study
Free
You need to be signed in to access email alerts. If you have an account log in with your user name and password. If you don't have an account you can just enter your email address in the email box below.
Sign In to Email Alerts with your Email Address